Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients

Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in Acute Coronary Syndromes Patients

The aim of this prospective cohort study was to investigate the multi-omics characteristics of the efficacy of colchicine treatment in patients with ACS and to construct a model of efficacy. The main questions the study aims to answer are

- Specific mechanisms of colchicine therapy in patients with ACS; Mechanism-based modelling to identify the population that benefits from colchicine treatment.

Inclusion Criteria:

• Between the ages of 18 and 80
• ACS (STEMI or NSTE-ACS)
• Patients to receive standardised drug therapy
• Able and willing to provide informed consent

Exclusion Criteria:

• Any contraindication to colchicine or known intolerance to colchicine
• Has been using colchicine for a prolonged period of time for other medical conditions
• Women of childbearing age who are pregnant, breastfeeding or not using effective contraception
• Coronary artery bypass grafting within the last 3 years or planned
• Severe hepatic impairment: elevated serum alanine aminotransferase and/or aminotransferase (ALT) and/or aminotransferase (AST) levels of up to three times the upper limit of normal
• Severe renal impairment: eGFR <30mL/min/1.73m2
• Thrombocytopenia (platelet count less than 100*10⁹/L)
• Active diarrhoea
• Infectious diseases: presence of uncontrollable infectious diseases
• Immune-related diseases: known immune diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumours, etc.
• Strong CYP3A4 or P glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) are already in use and no alternative medications can be administered
• Planning to use systemic anti-inflammatory therapies such as NSAIDs, hormones, immunomodulators and chemotherapeutic agents